Is DBD research on Rallies investment advice?

No. Rallies provides research, data, and educational context for DBD. It does not provide personalized investment advice.

DBD (Diebold Nixdorf, Incorporated) Stock Analysis - Financials

Diebold Nixdorf, Incorporated (DBD) is a publicly traded Technology sector company. As of October 5, 2026, DBD trades at $65.53 with a market cap of $2.16B and a P/E ratio of 21.33. DBD moved +2.92% today. Year to date, DBD is -3.33%; over the trailing twelve months it is +12.75%. Its 52-week range spans $34.88 to $92.09. Analyst consensus is buy with an average price target of $100.00. Rallies surfaces DBD's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What are DBD's key financials?

DBD financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. DBD recently traded at $65.53. Market cap is $2.16B. P/E ratio is 21.33. Revenue is $3.87B.

DBD Key Metrics

Key financial metrics for DBD
Metric	Value
Price	$65.53
Market Cap	$2.16B
P/E Ratio	21.33
EPS	$3.08
Dividend Yield	0.00%
52-Week High	$92.09
52-Week Low	$34.88
Volume	250.21K
Avg Volume	0
Revenue (TTM)	$3.87B
Net Income	$113.90M
Gross Margin	25.25%

DBD Analyst Consensus

2 analysts cover DBD: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $100.00.

Common questions about DBD

What are DBD's key financials?: DBD financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. DBD recently traded at $65.53. Market cap is $2.16B. P/E ratio is 21.33. Revenue is $3.87B.
Is DBD research on Rallies investment advice?: No. Rallies provides research, data, and educational context for DBD. It does not provide personalized investment advice.